Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV)

Neuropharmacology

Volumn 87, Issue , 2014, Pages 206-213

  Marusich, Julie A ^a   Antonazzo, Kateland R ^a   Wiley, Jenny L ^a   Blough, Bruce E ^a   Partilla, John S ^b   Baumann, Michael H ^b  

^a RTI INTERNATIONAL   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

3,4 Methylenedioxypyrovalerone; Functional observational battery; Locomotor activity; Monoamine transporter; Synthetic cathinones; PVP

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA PYRROLIDINOBUTIOPHENONE; ALPHA PYRROLIDINOPROPIOPHENONE; ALPHA PYRROLIDINOVALEROPHENONE; CATECHOLAMINE TRANSPORTER; CATHINONE; CENTRAL STIMULANT AGENT; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; BENZAZEPINE DERIVATIVE; DESIGNER DRUG; DOPAMINE RECEPTOR BLOCKING AGENT; PYRROLIDINE DERIVATIVE; RNA BINDING PROTEIN; SERT PROTEIN, RAT; SLC6A2 PROTEIN, RAT; STREET DRUG;

ADDICTION; ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG EFFECT; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; NONHUMAN; NORADRENALIN UPTAKE; RAT; SYNAPTOSOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; BENZAZEPINES; BENZODIOXOLES; BRAIN; CATECHOLAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; LOCOMOTION; MALE; MICE, INBRED ICR; MOTOR ACTIVITY; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PYRROLIDINES; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RNA-BINDING PROTEINS; STREET DRUGS; SYNAPTOSOMES;

EID: 84908505909     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.02.016     Document Type: Article

References (56)

1. S.M. Aarde, P.K. Huang, K.M. Creehan, T.J. Dickerson, and M.A. Taffe The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats Neuropharmacology 71 2013 130 140 10.1016/j.neuropharm.2013.04.003
2. American Association of Poison Control Centers Bath Salts Data 2012 Updated January 5, 2012
3. C. Bauer, M. Banks, B. Blough, and S. Negus Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats Br. J. Pharmacol. 168 2013 850 862 10.1111/j.1476-5381.2012.02214.x
4. M.H. Baumann, M.A. Ayestas Jr., J.S. Partilla, J.R. Sink, A.T. Shulgin, and P.F. Daley The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue Neuropsychopharmacology 37 2012 1192 1203 10.1038/npp.2011.304
5. M.H. Baumann, R.D. Clark, W.L. Woolverton, S. Wee, B.E. Blough, and R.B. Rothman In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat J. Pharmacol. Exp. Ther. 337 2011 218 225 10.1124/jpet.110.176271
6. M.H. Baumann, J.S. Partilla, and K.R. Lehner Psychoactive "bath salts": not so soothing Eur. J. Pharmacol. 698 2013 1 5
7. M.H. Baumann, J.S. Partilla, K.R. Lehner, E.B. Thorndike, A.F. Hoffman, and M. Holy Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive "bath salts" products Neuropsychopharmacology 38 2013 1 11 10.1038/npp.2012.204
8. S.D. Brandt, H.R. Sumnall, F. Measham, and J. Cole Analyses of second-generation "legal highs" in the UK: initial findings Drug. Test. Anal. 2 2010 377 382 10.1002/dta.155
9. R.W. Byard, G. Summersides, and A. Thompson Confluent muscle pallor: a macroscopic marker of cocaine-induced rhabdomyolysis Forensic. Sci. Med. Pathol. 7 2011 364 366 10.1007/s12024-011-9229-6
10. K. Cameron, R. Kolanos, R. Verkariya, L. De Felice, and R.A. Glennon Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter Psychopharmacology 227 2013 493 499 10.1007/s00213-013-2967-2
11. N.V. Cozzi, M.K. Sievert, A.T. Shulgin, P. Jacob, and A.E. Ruoho Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines Eur. J. Pharmacol. 381 1999 63 69
12. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) EMCDDA and Europol Step up Information Collection on Mephedrone 2010 Posted 03/11/13. Retrieved 8/26/13
13. A.J. Eshleman, K.M. Wolfrum, M.G. Hatfield, R.A. Johnson, K.V. Murphy, and A. Janowsky Substituted methcathinones differ in transporter and receptor interactions Biochem. Pharmacol. 85 2013 1803 1815 10.1016/j.bcp.2013.04.004
14. W.E. Fantegrossi, B.M. Gannon, S.M. Zimmerman, and K.C. Rice In vivo effects of abused "bath salt" constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity Neuropsychopharmacology 38 2013 563 573 10.1038/npp.2012.233
15. M.W. Fischman Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs NIDA Res. Monogr. 92 1989 211 230
16. A.E. Fleckenstein, J.W. Gibb, and G. Hanson Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity Eur. J. Pharmacol. 406 2000 1 13
17. M.B. Gatch, C.M. Taylor, and M.J. Forster Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones Behav. Pharmacol. 24 2013 437 447 10.1097/FBP.0b013e328364166d
18. D.V. Gauvin, and T.J. Baird A functional observational battery in non-human primates for regulatory-required neurobehavioral assessments J. Pharmacol. Toxicol. Methods 58 2008 88 93 10.1016/j.vascn.2008.05.002
19. B.A. Gosnell, J.M. Yracheta, S.M. Bell, and K.E. Lane Intravenous self-administration of cathinone by rats Behav. Pharmacol. 7 1996 526 531
20. G.C. Hadlock, K.M. Webb, L.M. McFadden, P.W. Chu, J.D. Ellis, and S.C. Allen 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse J. Pharmacol. Exp. Ther. 339 2011 530 536 10.1124/jpet.111.184119
21. L. Karila, and M. Reynaud GHB and synthetic cathinones: clinical effects and potential consequences Drug. Test. Anal. 3 2011 552 559 10.1002/dta.210
22. J. Kehr, F. Ichinose, S. Yoshitake, M. Goiny, T. Sievertsson, and F. Nyberg Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats Br. J. Pharmacol. 164 2011 1949 1958 10.1111/j.1476-5381.2011.01499.x
23. J.P. Kelly Cathinone derivatives: a review of their chemistry, pharmacology and toxicology Drug. Test. Anal. 3 2011 439 453 10.1002/dta.313
24. R. Lisek, W. Xu, E. Yuvasheva, Y.-T. Chiu, A.B. Reitz, and L.-Y. Liu-Chen Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation Drug. Alcohol Depend. 126 2012 257 262 10.1016/j.drugalcdep.2012.04.021
25. M.K. Lobo, and E.J. Nestler The striatal balancing act in drug addiction: distinct roles of direct and indirect pathway medium spiny neurons Front. Neuroanat. 5 2011 41 10.3389/fnana.2011.00041
26. R. López-Arnau, J. Martínez-Clemente, D. Pubill, E. Escubedo, and J. Camarasa Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone Br. J. Pharmacol. 167 2012 407 420 10.1111/j.1476-5381.2012.01998.x
27. L.J. Marinetti, and H.M. Antonides Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results J. Anal. Toxicol. 37 2013 135 146 10.1093/jat/bks136
28. J. Martínez-Clemente, E. Escubedo, D. Pubill, and J. Camarasa Interaction of mephedrone with dopamine and serotonin targets in rats Eur. Neuropsychopharmacol. 22 2012 231 236 10.1016/j.euroneuro.2011.07.009
29. J. Marusich, K.R. Grant, B.E. Blough, and J.L. Wiley Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice Neurotoxicology 33 2012 1305 1313 10.1016/j.neuro.2012.08.003
30. D.C. Mash, L. Duque, J. Pablo, Y. Qin, N. Adi, and W.L. Hearn Brain biomarkers for identifying excited delirium as a cause of sudden death Forensic Sci. Int. 190 2009 e13 e19 10.1016/j.forsciint.2009.05.012
31. P.C. Meltzer, D. Butler, J.R. Deschamps, and B.K. Madras 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors J. Med. Chem. 49 2006 1420 1432
32. C.P. Motbey, K.J. Clemens, N. Apetz, A.R. Winstock, J. Ramsey, and K.M. Li High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine J. Psychopharmacol. 27 2013 823 836 10.1177/0269881113490325
33. B.L. Murray, C.M. Murphy, and M.C. Beuhler Death following recreational use of designer drug "bath salts" containing 3,4-Methylenedioxypyrovalerone (MDPV) J. Med. Toxicol. 8 2012 69 75 10.1007/s13181-011-0196-9
34. National Research Council Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research 2011 National Academies Press Washington, DC
35. T.M. Penders, R.E. Gestring, and D.A. Vilensky Intoxication delirium following use of synthetic cathinone derivatives Am. J. Drug. Alcohol Abuse 38 2012 616 617 10.3109/00952990.2012.694535
36. Psychonaut Research Web Mapping Project MDPV Report 2009 Institute of Psychiatry, King's College London London, UK
37. E.A. Ross, M. Watson, and B. Goldberger "Bath salts" intoxication N. Engl. J. Med. 365 2011 967 968 10.1056/NEJMc1107097
38. R.B. Rothman, N. Vu, J.S. Partilla, B.L. Roth, S.J. Hufeisen, and B.A. Compton-Toth In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates J. Pharmacol. Exp. Ther. 307 2003 138 145
39. E. Samuel, R.B. Williams, and R.B. Ferrell Excited delirium: consideration of selected medical and psychiatric issues Neuropsychiatr. Dis. Treat. 5 2009 61 66
40. F. Schifano, A. Albanese, S. Fergus, J.L. Stair, P. Deluca, and O. Corazza Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues Psychopharmacology 214 2011 593 602 10.1007/s00213-010-2070-x
41. K.G. Shanks, T. Dahn, G. Behonick, and A. Terrell Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry J. Anal. Toxicol. 36 2012 360 371 10.1093/jat/bks047
42. L.D. Simmler, T.A. Buser, M. Donzelli, Y. Schramm, L.H. Dieu, and J. Huwyler Pharmacological characterization of designer cathinones in vitro Br. J. Pharmacol. 168 2013 458 470 10.1111/j.1476-5381.2012.02145.x
43. R.J. Smith, M.K. Lobo, S. Spencer, and P.W. Kalivas Cocaine-induced adaptations in D1 and D2 accumbens projection neurons (a dichotomy not necessarily synonymous with direct and indirect pathways) Curr. Opin. Neurobiol. 23 2013 546 552 10.1016/j.conb.2013.01.026
44. H.A. Spiller, M.L. Ryan, R.G. Weston, and J. Jansen Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States Clin. Toxicol. 49 2011 499 505 10.3109/15563650.2011.590812
45. U.S. Congress Synthetic Drug Abuse Prevention Act 2012 1 6
46. U.S. Drug Enforcement Administration Synthetic Cannabinoids and Cathinones - DEA Request for Information 2013 Posted 01/22/13. Retrieved 8/26/13
47. U.S. Drug Enforcement Administration, Office of Diversion Control National Forensic Laboratory Information System: Midyear Report 2012 2013 U.S. Drug Enforcement Administration Springfield, VA https://www.nflis.deadiversion.usdoj.gov
48. U.S. Environmental Protection Agency (U.S. EPA) Guidelines for Neurotoxicity Risk Assessment. Risk Assessment Forum 1998 U.S. EPA Washington, DC 630/R-95/001F. Available from: http://www.epa.gov/raf/publications/guidelinesneurotoxicity-risk-assessment.htm
49. U.S. Environmental Protection Agency (U.S. EPA) Health Effects Guidelines: Neurotoxicity Screening Battery 1998 U.S. EPA Washington, DC EPA 712-C-98-238. OPPTS 870.6200. Available from: http://www.epa.gov/ocspp/pubs/frs/publications/Test-Guidelines/series870.htm
50. L.R. Watterson, L. Hood, K. Sewalia, S.E. Tomek, S. Yahn, and C.T. Johnson The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in "bath salts" J. Addict. Res. Ther. S9 002 2012 10.4172/2155-6105.S9-002
51. L.R. Watterson, P.R. Kufahl, N.E. Nemirovsky, K. Sewalia, M. Grabenauer, and B.F. Thomas Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) Addict. Biol. 2012 10.1111/j.1369-1600.2012.00474.x
52. S. Wee, K.G. Anderson, M.H. Baumann, R.B. Rothman, B.E. Blough, and W.L. Woolverton Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs J. Pharmacol. Exp. Ther. 313 2005 848 854
53. A.R. Winstock, L.R. Mitcheson, P. Deluca, Z. Davey, O. Corazza, and F. Schifano Mephedrone, new kid for the chop? Addiction 106 2011 154 161 10.1111/j.1360-0443.2010.03130.x
54. A.R. Winstock, and J.D. Ramsey Legal highs and the challenges for policy makers Addiction 105 2010 1685 1687 10.1111/j.1360-0443.2010.03163.x
55. M.J. Wright Jr., D. Angrish, S.M. Aarde, D.J. Barlow, M.W. Buczynski, and K.M. Creehan Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats PLoS One 7 e 2012 44652 10.1371/journal.pone.0044652
56. J.F. Wyman, E.S. Lavins, D. Engelhart, E.J. Armstrong, K.D. Snell, and P.D. Boggs Postmortem tissue distribution of MDPV following lethal intoxication by "bath salts" J. Anal. Toxicol. 37 2013 182 185 10.1093/jat/bkt001